HOOK Stock Overview
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
HOOKIPA Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.76 |
| 52 Week High | US$2.05 |
| 52 Week Low | US$0.41 |
| Beta | 1.02 |
| 1 Month Change | 4.03% |
| 3 Month Change | 15.86% |
| 1 Year Change | 6.24% |
| 3 Year Change | -93.81% |
| 5 Year Change | -94.59% |
| Change since IPO | -94.54% |
Recent News & Updates
Recent updates
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24
Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts
May 18Hookipa: Speculative Biotech With Key Catalysts In 2022
Mar 29Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Oct 01Checking Back In On HOOKIPA Pharma
Jun 22Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers
Jun 08Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Apr 19If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns
Mar 15What Kind Of Shareholders Hold The Majority In HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shares?
Jan 22
Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside
Dec 31Introducing HOOKIPA Pharma (NASDAQ:HOOK), A Stock That Climbed 55% In The Last Year
Dec 11HOOKIPA Pharma prices public offering of common stock and preferred stock
Dec 09Shareholder Returns
| HOOK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | -4.2% | -3.7% |
| 1Y | 6.2% | -2.0% | 20.5% |
Return vs Industry: HOOK exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: HOOK underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| HOOK volatility | |
|---|---|
| HOOK Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HOOK has not had significant price volatility in the past 3 months.
Volatility Over Time: HOOK's weekly volatility has decreased from 15% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 165 | Joern Aldag | www.hookipapharma.com |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial.
HOOKIPA Pharma Inc. Fundamentals Summary
| HOOK fundamental statistics | |
|---|---|
| Market cap | US$75.45m |
| Earnings (TTM) | -US$81.58m |
| Revenue (TTM) | US$20.13m |
3.8x
P/S Ratio-0.9x
P/E RatioIs HOOK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOOK income statement (TTM) | |
|---|---|
| Revenue | US$20.13m |
| Cost of Revenue | US$85.08m |
| Gross Profit | -US$64.95m |
| Other Expenses | US$16.63m |
| Earnings | -US$81.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.82 |
| Gross Margin | -322.66% |
| Net Profit Margin | -405.29% |
| Debt/Equity Ratio | 1.2% |
How did HOOK perform over the long term?
See historical performance and comparison